cycloheximide

Small moleculeexperimental

Cycloheximide is a naturally occurring fungicide produced by the bacterium Streptomyces griseus. Cycloheximide exerts its effects by interfering with the translocation step in protein synthesis, thus blocking eukaryotic translational elongation. Cycloheximide is widely used in biomedical research to inhibit protein synthesis in eukaryotic cells studied in vitro. It is inexpensive and works rapidly. Its effects are rapidly reversed by simply removing it from the culture medium. — Wikipedia

Clinical trial activity

2 trials · 5 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Feb 1, 1999 (NCT00133302)

Timeline

1990s

Jan 1, 1999
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Lymphoma, Non-Hodgkin · Phase 3

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1

Mol. weight: 281.35 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaCycloheximide ↗
ChEMBLCHEMBL123292 ↗

Also known as

cycloheximide
cycloheximide

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00554164	Phase 3	Nov 1, 2007	Deutsche Krebshilfe e.V., University of Duisburg-Essen
NCT00133302	Phase 3	Feb 1, 1999	Government of Japan, Japan Clinical Oncology Group, Tokai University

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (5)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Deutsche Krebshilfe e.V.	Academic/Hospital	1	0	1	2007
Government of Japan	Government	1	0	1	1999
Japan Clinical Oncology Group	Academic/Hospital	1	1	1	1999
Tokai University	Academic/Hospital	1	0	1	1999
University of Duisburg-Essen	Academic/Hospital	1	1	1	2007

5 organizations

Page 1 / 1